Caplin Point Laboratories Limited has informed the Exchange regarding Cessation of Umesh Setty V as Senior Vice President, R&D (Formulations), a SMP of the company w.e.f. May 07, 2025.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mr. Umesh Setty V, Senior Vice President – R&D (Formulations) and a Senior Management Personnel of Caplin Point Laboratories, has resigned with effect from the close of working hours on May 07, 2025. The reason cited is personal – his mother's deteriorating health, requiring him to step away from professional responsibilities. The company has stated that a suitable replacement has been identified and will join in due course. The resignation letter indicates willingness to support a smooth transition during the notice period.
An SVP-level R&D (Formulations) exit is notable for a pharma company, but the personal nature of the resignation and the company's confirmation of an identified replacement limit near-term disruption. Investors should watch for the successor announcement to gauge continuity in the formulations R&D pipeline.